American Society of Hematology 49th Annual Meeting: Nilotinib (Tasigna) in chronic myelogenous leukemia

P and T

Volumn 33, Issue 2, 2008, Pages

  Alexander, Walter ^a   Le Coutre, Philipp ^a  

^a Humboldt Universität ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; IMATINIB; NILOTINIB; DASATINIB;

ADULT; ANEMIA; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; NEUTROPENIA; OVERALL SURVIVAL; PHILADELPHIA 1 CHROMOSOME; RASH; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; HEADACHE; HEMATOLOGIC DISEASE; INFECTION; MUSCULOSKELETAL PAIN; PLEURA EFFUSION; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE;

EID: 40949161458     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (1)

1. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision making. J Clin Oncol 2005;23:7594-7603.